header logo image


Page 693«..1020..692693694695..700710..»

Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer – Xconomy

February 8th, 2020 3:48 am

XconomySan Francisco

Cell therapies have reached the market as a new treatment option for some cancers. But the scientists of Sonoma Biosciences say this approach also holds promise for autoimmune disorders, and the biotech startup has unveiled $40 million in financing to develop its technology.

The investors in Sonomas Series A round of funding include Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures, and 8VC.

Cell therapy involves removing a patients immune cells, engineering them, and then infusing them back into the patient to perform their therapeutic tasks. The cancer cell therapies that have been approved by the FDA are made by engineering T cells, the frontline defenders of the immune system.

Sonoma, which splits its operations between South San Francisco and Seattle, is working with a different immune cell called a regulatory T cell (Treg). Whereas T cells target pathogens, Tregs target other immune cells, suppressing excessive immune responses, CEO and co-founder Jeff Bluestone tells Xconomy. Research by Sonomas scientific co-founders uncovered evidence, in studies in mice and humans, that the absence of these cells sparked the development of some autoimmune diseases. Those diseases led to death in about one year without a bone marrow transplant, Bluestone adds.

Sonoma is developing Treg therapies intended to shut down unwanted immune responses. The approach involves harvesting these cells from patients and engineering them with features that make them stable, durable, and targeted specifically to the site of inflammation. Those cells would then be infused into the patient to stop the autoimmune response. Bluestone says its too soon to talk about a lead disease target, but he adds that this approach has potential applications in rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

The hope is that a Sonoma cell therapy is a one-time treatment. Bluestone says that because these therapies are cells that multiply, they should survive in the patient on standby until theyre needed again to address an autoimmune response.

Theres another feature that could contribute to the longevity of a Treg treatment. When these cells shut down an autoimmune response, they influence other cells in the vicinity to join in, Bluestone explains. By educating these other cells to take up this immunosuppressive role, Bluestone says the effect of these therapies could be long lasting. But he cautions that the durability of a Treg therapy wont be known until more tests are done in humans.

Bluestones knowledge about Tregs stems from his own research. He and another Sonoma co-founder, Qizhi Tang, studied Tregs at the University of California, San Francisco, for 12 years. Their research included diabetes, organ transplantation, and lupus, among other conditions. That work led to small patient studies testing the technology for safety.

In addition to his UCSF research, Bluestone was the president and CEO of the Parker Institute for Cancer Immunotherapy. Over the course of a career that has bridged academia and industry, Bluestones immunology research has led to the development and commercialization of immunotherapies for organ transplants and cancer. He says he is joining Sonoma now because theres only so far that you can get in an academic lab if you want to impact peoples lives. Cell therapy could be the next major medicine for humans, he adds, and he wants to be involved as part of a company developing these treatments.

The other co-founders are Chief Scientific Officer Fred Ramsdell who, like Bluestone, joined Sonoma from the Parker Institute, and Alexander Rudensky, an immunologist at the Memorial Sloan Kettering Cancer Center. Ramsdell and Rudensky are credited as co-discoverers of the FOXP3 gene that is critical to the development and function of Tregs.

Bluestone says that Sonoma continues the Treg research that he and the other co-founders had done. The company also builds on the successes and failures in cancer cell therapy research. While those therapies can treat blood cancers, its been much harder to use them to treat solid tumors. Bluestone hopes that Lyell, a South San Francisco cell therapy company, can help the company get its therapies into tissues. In addition to being a Sonoma investor, Bluestone says Lyell will be a research partner, providing access to its technology and cell therapy insights.

Sonoma also aims to go beyond autoimmune diseases. Bluestone says the companys approach could potentially address degenerative disorders, such as amyotrophic lateral sclerosis and Alzheimers disease. In the nearer term, Bluestone says the company will use the funding to better understand Tregs.

The way were approaching this field is not to be in a hurry, in a sense of feeling this pressure or need to get into the clinic with these engineered cells as quickly as possible, he says. We want to spend the time to make sure were working with the best cells possible, that we understand the science and the biology, so that it has the best chance of success.

Public domain image by Flickr user NIH Image Gallery

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan [[at]] xconomy.com.

View original post here:
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer - Xconomy

Read More...

High Levels of PFAS Affect Immune, Liver Functions in Cape Fear River Striped Bass – NC State News

February 8th, 2020 3:48 am

Researchersfrom North Carolina State University have found elevated levels of 11 per- andpolyfluoroalkyl (PFAS) chemicals in the blood of Cape Fear River striped bass.Two of those compounds perfluorooctane sulfonate (PFOS) and Nafion byproduct2 are associated with altered immune and liver functions in those fish.

Scott Belcher, associate professor of biology and corresponding author of a paper describing the research, led a team that included NCState colleagues Detlef Knappe, Ben Reading and postdoctoral researcher Theresa Guillette as well as partners from the North Carolina Wildlife Commission and the U.S. Environmental Protection Agency (EPA).

Theteam isolated serum from the blood of 58 wild caught Cape Fear River stripedbass ranging in age from 2 to 7 years old. In collaboration with EPA researchersMark Stryner and James McCord, they determined the concentrations of 23different PFAS chemicals present in the serum using a combination of liquidchromatography and high-resolution mass spectrometry.

Testingblood levels gives you an idea of the body burden of these particularchemicals, Belcher says. The levels of these chemicals in the water weremeasured in parts per trillion, but in the serum of the fish levels are higherand in parts per billion, demonstrating that they have clearly bioaccumulatedin these fish.

Theteam then compared the blood serum samples from the wild caught fish to thosefrom a reference population of 29 striped bass raised in an aquaculturefacility fed by ground water. The serum levels of chemicals in the wild caughtbass were 40% higher, on average, than the background levels found in thisreference population, Belcher says.

Incomparison to the levels of PFAS found in Cape Fear River water, elevatedlevels of PFOS and Nafion byproduct 2 were found in 100% and 78% of the wildbass samples, respectively. The serum concentrations of these compounds wereassociated with biomarkers of altered liver enzyme activity and immune functionin those fish.

ThesePFAS levels are some of the highest recorded in fish, Belcher says, but oneof the most unusual findings here is that smaller or younger fish had thehighest levels of these compounds. This points to the fact that PFAS chemicalsare very different from other persistent chemicals, like mercury or PCBs. Theyhave unique and very different chemical properties that cause them tobioaccumulate differently, and were really just beginning to understand whyand how they do what they do.

The work appears in Environment International, and was supported in part by the National Institute of Environmental Health Sciences (award numbers P30ES025128 and R21ES029353), and a North Carolina Sea Grant Community Collaborative Research Grant. Theresa Guillette is first author. Matthew Guillette, M.E. Polera and Nadine Kotlarz from NCState, as well as Kyle Rachels and Clint Morgeson from the N.C. Wildlife Resources Commission, also contributed to the work.

-peake-

Note to editors: An abstract follows.

ElevatedPer- and Polyfluoroalkyl Substances in Cape Fear River Striped Bass (Morone saxatilis) are Associatedwith Biomarkers of Altered Immune and Liver Function

DOI: 10.1016/j.envint.2019.105358

Authors: T.C. Guillette, Matthew Guillette, M.E. Polera, NadineKotlarz, Detlef Knappe, Benjamin J. Reading, Scott Belcher, North CarolinaState University; James McCord, Mark Strynar, National Exposure Research Laboratory,ORD, U.S. EPA, Research Triangle Park, North Carolina; Kyle Rachels, ClintMorgeson, N. C. Wildlife Resources Commission, Inland Fisheries DivisionRaleigh, NC

Published: Feb. 7 in Environment International

Abstract:Per- and polyfluoroalkyl substances (PFAS)are anthropogenic chemicals of concern that persist within the environment.Environmental monitoring revealed high concentrations of hexafluoropropyleneoxide dimer acid (HFPO-DA) and other novel PFAS in the lower Cape Fear River;however, there is limited information on PFAS exposures and effects of thiscontamination on aquatic biota. Serum concentrations of 23 different PFAS inStriped Bass (Morone saxatilis) fromthe Cape Fear River (n=58), and a reference population from an aquaculturelaboratory on the Pamlico/Tar watershed (n=29), were quantified using liquidchromatography, high-resolution mass spectrometry, and correlations betweenPFAS concentrations and health-related serum biomarkers were evaluated.Perfluorooctane sulfonate, the predominant PFAS in Cape Fear River Striped Bassserum, was detectable in every sample with serum concentrations reaching 977ng/mL. Perfluorononanoic and perfluorodecanoic acid were also detected in allsamples, with perfluorohexanesulfonic acid present in >98% of the samples.HFPO-DA (range <0.24-5.85 ng/mL) and Nafion byproduct 2 (range <0.21.03ng/mL) were detected in 48% and 78% of samples, respectively. The mean totalPFAS concentration found in domestic Striped Bass raised in well-water under controlled aquacultureconditions was 40 times lower, with HPFO-DA detected in 10% of the samples, andNafion byproduct 2 not detected. The elevated PFAS concentrations found in theCape Fear River Striped Bass were associated with biomarkers of alterations inthe liver and immune system.

Read more here:
High Levels of PFAS Affect Immune, Liver Functions in Cape Fear River Striped Bass - NC State News

Read More...

The Coronavirus Started in Animals. That Makes it More Dangerous. – Futurism

February 8th, 2020 3:48 am

The coronavirus that emerged in China and rapidly spread around the world almost certainly jumped to humans from an animal. While thats certainly not unheard of, scientists are on high alert because zoonotic viruses, as theyre called, can potentially be more dangerous.

The heightened risk associated with animal-borne diseases like 2019-nCoV comes from the fact that our immune systems have never had the chance to build up resistance to them, according to New Scientist.

From an evolutionary perspective, a successful virus is one that develops to spread rapidly and rampantly something that depends on the survival of its host.

They dont want you to drop dead within a day because you wont pass it to anyone else, University of Nottingham researcher Chris Coleman told New Scientist.

Recent research in the journal Nature suggests that the coronavirus emerged in bats rather than an earlier snake hypothesis.

In either case, its cause for concern. When zoonotic viruses jump to humans, they can be far more deadly than they were in their animal host because theyveadapted to that animals immune systemrather than ours.

Thus far, the coronavirus outbreak has had a lower fatality rate than other zoonotic diseases, New Scientist reports, but its particularly adept at spreading among humans.

But to fight deadly outbreaks in the future, Coleman stressed the value of preparing broad-spectrum vaccines in advance something still missing for the coronavirus.

See the original post here:
The Coronavirus Started in Animals. That Makes it More Dangerous. - Futurism

Read More...

3 Canadian Biotechs to Consider Buying Today – The Motley Fool

February 8th, 2020 3:48 am

Innovation knows no borders allowing adventurous biotech investors the opportunity to find hidden gems located outside the major research and development hubs in the U.S., Europe, and Japan. One doesn't even need to look too far.

Here we previewthree such companies hailing from Canada, specifically the greater Vancouver area, which boastpromising drugs in their pipelines and just raised additional financing from savvy insitutional investors eager to get ahead of the curve. These emerging biotechs may be the ticket for risk-tolerant investors to boost their portfolios.

Image source: Getty Images.

Biotech investors are taking note of Vancouver-based Zymeworks (NYSE:ZYME). In the last year, the stock steadily tripled from $15 to its current price of $46. Last week, the company announced it successfully raised $320.8 million, primarily from institutional investors.

Zymeworks engineers antibodies, a component of the immune system, to selectively recognize distinct targets on cancer cells. Each molecule can identify two separate targets leading to their name bispecific antibodies. Zymeworks did not stop there. In some cases, the company attaches highly potent cancer-killing drugs to the bispecific molecule using it as a targeting system. This is called an antibody drug conjugate and potentially increases the ability to kill cancer cells.

One of many companies battling breast cancer, Zymeworks initially began development against a set of aggressive cancers that contain the human epidermal growth factor receptor 2 (HER2) gene. The HER2 gene helps regulate cell division, growth, and repairs. Aberrant amounts of the gene can lead to excessive growth of cancer cells. Beyond breast cancer, HER2 overexpression or amplification is found in certain cancers of the stomach, pancreas, and salivary gland, to name a few.

Lead compound ZW25 targets two unique variants of HER2, and has entered a slate of human clinical trials. The antibody drug conjugate version called ZW49 is in early stage clinical trial testing.

A review of Zymeworks' pipeline shows a long list of drug candidates being developed in collaboration with other companies. These include pharma stalwarts Eli Lilly, Merck, Bristol-Myers Squibb, Johnson & Johnson, and emerging China-based pharma BeiGene.

Targeting neurological disorders, Xenon Pharmaceuticals (NASDAQ:XENE) recently raised an additional $60 million in financing to advance its pipeline. This comes on the heels of receiving $50 million from a new partnership. This capital infusion should provide enough resources to advance its four clinical stage drug candidates forward.

Xenon plans to advance XEN496 into a pivotal phase 3 clinical trial for a rare and severe form of childhood epilepsy. Towards the end of 2020, the company expects results from a phase 2b trial with XEN1101 as a treatment for adults with focal epilepsy. In this disease, recurring seizures emerge from a specific part of the brain.

Like Zymeworks, Xenon boasts prominent strategic partners. Genentech, part of the Roche Group, forged a collaboration to pursue a novel approach to treating pain. Following an initial discovery collaboration, Merck acquired the rights to a compound as a treatment for cardiovascular disease.In September, Xenon entered a partnership with biotech Flexion Therapeutics to develop an extended-release thermosensitive hydrogel version of Xenon's XEN402 for post-operative pain.

Last December, Neurocrine Biosciencesentered into a partnership to develop novel epilepsy treatments. The pact grants rights to Xenon's clinical-stage epilepsy drug XEN901 and a multi-year collaboration to discover new drug candidates. Neurocrine paid $50 million consisting of $30 million in cash and a $20 million equity investment. Xenon could potentially earn development, regulatory, and commercial milestones totaling approximately $1.7 billion for XEN901 and other collaboration programs.

Last December was a whirlwind for Aurinia Pharmaceuticals (NASDAQ:AUPH). First, the company announced positive results from a phase 3 clinical trial of its drug voclosporin in lupus nephritis, a dangerous kidney disease caused by the body's immune system attacking healthy tissues. The company plans to file for approval with the U.S. Food and Drug Administration sometime in the first half of 2020. Aurinia plans a commercial launch of the product, assuming approval, in the first half of 2021.

Investors excited by the trial results drove up the stock price from the $5 range to the high teens. When the stock was in the $18 range, management at Aurinia opportunistically raised $191.7 million at $15 per share. With more money in the bank, investors clamored for the stock pushing the shares to $21, a four-fold gain from where the stock traded prior to the clinical trial results.

Beyond lupus nephritis, Aurinia has commenced clinical testing of voclosporin in dry eye syndrome and focal segmental glomerulosclerosis (FSGS). Chronic in nature, the hallmarks of dry eye syndrome are irritation and inflammation. FSGS, a rare disease that attacks the kidneys' filtering system and can be potentially life-threatening, has no FDA-approved treatments.

Zymeworks feels like Seattle Geneticsin its earlier days. Leveraging expertise in a core technology, it produced a broad array of wholly owned and partnered drugs. Investors should watch for clinical results from ZW25 and ZW49. With a $2 billion valuation, a big pharma or biotech could swoop in to pick up this promising biotech.

Xenon, the smallest of the three companies by market capitalization, really needs the top-line results with XEN1101 in epilepsy to be positive. The trial results are expected in the second half of the year. While investing in R&D stage biotech is risky, Xenon needs to deliver more data to provide investors more comfort.

As a single-product company, Aurinia appears to be a likely acquisition target in the rare disease space. Voclosporin faces competition from GlaxoSmithKline, but, perhaps, a company like Pfizer, which has its own program in FSGS, could be a suitor.

Read the original:
3 Canadian Biotechs to Consider Buying Today - The Motley Fool

Read More...

Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? – Genetic Literacy Project

February 8th, 2020 3:47 am

In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.

The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.

By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)

Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.

Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.

While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.

When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?

Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.

The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.

As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.

Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?

In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.

First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.

Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.

But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.

What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.

In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.

But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.

There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.

I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.

There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.

So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?

So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.

So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.

Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.

The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.

Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.

It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.

Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.

Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!

If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.

At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.

One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.

I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.

A version of this story originally ran on the GLP on April 16, 2018.

Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc

Go here to read the rest:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project

Read More...

Researchers identify roots of childhood asthma – European Biotechnology

February 8th, 2020 3:47 am

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with the behaviour of the immune system early in life a finding that could open the door to new diagnostics and preventative strategies.

The immune system develops as immune cells begin to respond to different types of microbes from the environment. This early stage of development is critical: any persistent abnormalities can trigger chronic inflammation and may raise the risk of asthma and other allergic diseases.

To flesh out the connection between early-life immunity and asthma, first author Anna Thysen et al. studied a longitudinal cohort of 541 children, by analysing blood samples collected at 18 months and comparing these immune profiles to clinical outcomes at six years of age. The scientists exposed blood cells gathered from the 18 month olds to different molecules from viruses, bacteria and fungi. They observed that neutrophils of the innate immune system from some infants responded too strongly to certain viruses, and these same infants were more susceptible to transient asthma as they approached the age of six. Furthermore, some infants harboured T cells that produced excessive amounts of IL-5 and IL-13 two pro-inflammatory cytokines associated with asthma and were more likely to have developed persistent asthma at six years of age.

Thysenet al.speculate that future blood tests to detect abnormal immune signatures in infants might allow for earlier prevention or treatment of childhood asthma.

See the original post:
Researchers identify roots of childhood asthma - European Biotechnology

Read More...

Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? – InvestorsObserver

February 8th, 2020 3:47 am

The 66 rating InvestorsObserver gives to Esperion Therapeutics Inc (ESPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, ESPRs 66 overall rating means the stock scores better than 66 percent of all stocks.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Esperion Therapeutics Inc (ESPR) stock has gained 7.95% while the S&P 500 has fallen -0.25% as of 11:33 AM on Friday, Feb 7. ESPR has gained $4.61 from the previous closing price of $57.98 on volume of 444,201 shares. Over the past year the S&P 500 is higher by 23.33% while ESPR has gained 38.57%. ESPR lost -$3.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the article here:
Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? - InvestorsObserver

Read More...

Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE – Simply Wall St

February 8th, 2020 3:47 am

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, well use ROE to better understand Avecho Biotechnology Limited (ASX:AVE).

Over the last twelve months Avecho Biotechnology has recorded a ROE of 2.5%. One way to conceptualize this, is that for each A$1 of shareholders equity it has, the company made A$0.03 in profit.

Check out our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Avecho Biotechnology:

2.5% = AU$158k AU$6.2m (Based on the trailing twelve months to June 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. The easiest way to calculate shareholders equity is to subtract the companys total liabilities from the total assets.

Return on Equity measures a companys profitability against the profit it has kept for the business (plus any capital injections). The return is the profit over the last twelve months. A higher profit will lead to a higher ROE. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Avecho Biotechnology has a lower ROE than the average (7.7%) in the Pharmaceuticals industry.

That certainly isnt ideal. Wed prefer see an ROE above the industry average, but it might not matter if the company is undervalued. Nonetheless, it might be wise to check if insiders have been selling.

Most companies need money from somewhere to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

Avecho Biotechnology is free of net debt, which is a positive for shareholders. Without a doubt it has a fairly low ROE, but that isnt so bad when you consider it has no debt. At the end of the day, when a company has zero debt, it is in a better position to take future growth opportunities.

Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have the same ROE, then I would generally prefer the one with less debt.

But when a business is high quality, the market often bids it up to a price that reflects this. It is important to consider other factors, such as future profit growth and how much investment is required going forward. Check the past profit growth by Avecho Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read this article:
Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE - Simply Wall St

Read More...

Here’s Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today – Motley Fool

February 8th, 2020 3:47 am

What happened

Shares of Inovio Pharmaceuticals (NASDAQ:INO) and Vir Biotechnology (NASDAQ:VIR), two companies developing drugs for the coronavirus outbreak in China, are down today on word that Gilead Sciences (NASDAQ:GILD) looks to have beaten the companies to the punch, setting up a research collaboration with Chinese authorities to run a clinical trial for its antiviral medication remdesivir.

As of 1:46 p.m. EST on Monday, Inovio had fallen 14.5%, while Vir was down 16.2%.

Image source: Getty Images.

While the news that Gilead has moved first is disappointing for the biotechs, there may still be a need for Inovio's 2019-nCoV coronavirus vaccine. Remdesivir might lessen the symptoms of the virus, but it won't stop the spread of the disease in mildly symptomatic patients who aren't likely to take the drug.

Vir's antibody treatment would likely compete more directly with remdesivir since it would attack the virus directly and would likely be used to treat infected patients.

Both Inovio and Vir increased in value quite a bit in January. Vir doubled, while Inovio was up almost 40% as the 2019-nCoV coronavirus outbreak has spread and investors pinned hopes on the potential to develop drugs for the virus. With the valuations already incorporating some of the potential, it's not surprising to see a pullback on news that the opportunity might not be as large as first imagined.

The bigger issue for Inovio and Vir is how long the clinical trial process could end up taking and whether the outbreak will peter out before the companies can get their treatments to market.

Continue reading here:
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today - Motley Fool

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts…

February 8th, 2020 3:47 am

New Jersey, United States The report is a comprehensive research study of the global Nanoparticles in Biotechnology and Pharmaceuticals market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

This report covers a comprehensive study of the data affecting the Nanoparticles in Biotechnology and Pharmaceuticals market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Nanoparticles in Biotechnology and Pharmaceuticals market.

Key players in global Nanoparticles in Biotechnology and Pharmaceuticals market include:

Roche, GE Healthcare, Merck, Novartis, AMAG Pharmaceuticals, Amgen, Bausch & Lomb, Biogen, Celgene, Gilead, Ipsen, Leadiant Biosciences, nanoComposix, Pacira Pharmaceuticals, Pfizer, Shire

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=ITN&utm_medium=003

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Nanoparticles in Biotechnology and Pharmaceuticals s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Nanoparticles in Biotechnology and Pharmaceuticals Market:

Nanoparticles in Biotechnology and Pharmaceuticals market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Nanoparticles in Biotechnology and Pharmaceuticals Market: Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model

5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution

6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical

7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=ITN&utm_medium=003

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Verified Market Research

Read the original post:
Nanoparticles in Biotechnology and Pharmaceuticals Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts...

Read More...

Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 – Instant Tech News

February 8th, 2020 3:47 am

New Jersey, United States The report is a comprehensive research study of the global Red Biotechnology market, taking into account growth factors, recent trends, developments, opportunities and the competitive landscape. Market analysts and researchers performed an in-depth analysis of the Red Biotechnology global market using research methodologies such as PESTLE and Porters Five Forces analysis. They provided precise and reliable data on the market and useful recommendations in order to help the actors to better understand the global scenario of the present and future market. The report includes an in-depth study of potential segments, including product type, application and end user, as well as their contribution to the overall size of the market.

Red Biotechnology Market was valued at USD 314.2 Billion in 2018 and is projected to reach USD 503 Billion by 2026, growing at a CAGR of 5.7% from 2019 to 2026.

This report covers a comprehensive study of the data affecting the Red Biotechnology market with regard to manufacturers, suppliers, market players and customers. The report also includes an overview of technology applications and strategies used by market leaders. In addition to data compiled by type, application and region, the study includes personalized research to examine the intricacies of the global Red Biotechnology market.

Key players in global Red Biotechnology market include:

Amgen F. Hoffmann-La Roche, Gilead Sciences CSL, Pfizer Inc

Get Complete SWOT Analysis Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=11405&utm_source=ITN&utm_medium=005

Global Red Biotechnology Market: Research Methodology

The research methodology used by analysts play an integral role in how the publication has been prepared. Analysts have used primary and secondary research methodologies to make a comprehensive analysis. For accurate and precise analysis of the global Red Biotechnology s market, analysts have a bottom-up and top-down approaches.The main sources include interviews, surveys and observations of seasoned analysts, and secondary sources cover reputable paid sources, trade journals and databases of industry organizations. Other research methods include SWOT analysis with In-Depth Market Analysis.

Drivers & Constraints of Red Biotechnology Market :

Red Biotechnology market competitiveness is the result of the expansion technique employed by market leaders. market dynamics and trends play an important role in this growth market. This report focuses on the value chain, the trend of volume and price factors that influence the market. The growth of world population and the constant evolution of consumer demand is the main cause of the market dynamics. In addition, market restrictions and limits and strategies used by companies to overcome these limits are included in market research.

Global Red Biotechnology Market : Regional Analysis

This part of the report includes detailed information on the market in various regions. Each region offers different scope for markets because every region has a different government policies and other factors. The regions included in this report are North America, Europe, Asia Pacific, and the Middle East and Africa. Information about the different areas helps the reader to understand better the global market.

Table of Content

1 Introduction of Red Biotechnology Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Red Biotechnology Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Red Biotechnology Market , By Deployment Model

5.1 Overview

6 Red Biotechnology Market , By Solution

6.1 Overview

7 Red Biotechnology Market , By Vertical

7.1 Overview

8 Red Biotechnology Market , By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Red Biotechnology Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Check Complete Report For Deep SWOT Analysis Updates @ https://www.verifiedmarketresearch.com/product/red-biotechnology-market/?utm_source=ITN&utm_medium=005

Our Report offers:

About Us

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]iedmarketresearch.com

Red Biotechnology Market Size, Red Biotechnology Market Analysis, Red Biotechnology Market Growth, Verified Market Research

Go here to read the rest:
Red Biotechnology Market 2020 | Research, Opportunities, Emerging Trends, Competitive Strategies and Forecasts 2020-2026 - Instant Tech News

Read More...

Biotech stocks get a boost from coronavirus fears — but here’s why investors should be wary – Yahoo Finance

February 8th, 2020 3:47 am

Pharmaceutical stocks, which have seen temporary spikes during the coronavirus crisis as investors bet on the possibility of a vaccine, may be getting ahead of themselves.

Markets are speculating that some products may prove instrumental in the fight against the deadly disease, which has infected thousands in China, left 200 dead and rattled global markets.

However, biotech experts say that buyers should certainly be wary of trying to trade on coronavirus fears, given that most companies lack an established track record or are simply trying to position themselves to benefit from public health crisis.

Theres two things that biotech companies, especially small ones, are always looking for: Attention and cash, Brad Loncar, a biotech investor, told Yahoo Finance on Friday.

And, sadly, a lot of them take advantage of situations...putting out a press release saying they are working on something and you see their stocks zoom, Loncar added.

To be sure, not all pharma companies are created equal. To fight the coronavirus, large cap companies like Johnson & Johnson (JNJ), AbbVie (ABBV) and Gilead Sciences (GILD) announced they were repurposing HIV, Ebola and Zika products that had been developed but are not on the market to create a vaccine. Separately, Roche is planning to disseminate testing kits for the virus.

Meanwhile, China and Hong Kongs biotech companies may hold more promise for finding a treatment or cure, amid a rise of domestic Chinese companies competing with U.S. or European brands.

A lot of people dont know theres a biotech boom happening in China today, according to Loncar, who manages a Chinese biotech exchange-traded fund. Its an example that China can rise to this call.

People wear face masks and walk at a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. People wear face masks as they walk through a shopping mall in Taipei, Taiwan, Friday, Jan. 31, 2020. According to the Taiwan Centers of Disease Control (CDC) Friday, the tenth case diagnosed with the new coronavirus has been confirmed in Taiwan. (AP Photo/Chiang Ying-ying)

Yet finding effective treatments and cures for the virus is easier said than done. It took five years for the first Ebola vaccine to hit the market, and the coronavirus vaccine is likely to follow the same pattern.

Barring a dramatic breakthrough, it means the sickness could rage for an extended period before a solution is found which means investors should be particularly careful about sinking money into biotech and pharma companies making big promises.

That includes stocks of smaller companies, which saw fleeting rallies last week on vaccine speculation. Inovio (INO), Moderna (MRNA), Novavax (NVAX), Meridian Biosciences (VIVO), Vir Biotechnology (VIR) and BioCryst (BCRX). Virtually all of them have pared or completely reversed the weeks initial gains.

Its important to know how big the potential universe for any vaccine is likely to be, Chris Meekins, a biotech analyst, told Yahoo Finance this week.

So companies that have a partnership with the government those would be areas that are better to invest in than companies that dont have government funding, because I dont believe theres a sustained investment, he added.

Robert W. Baird research analyst Brian Skorney told Yahoo Finance the companies who do end up making something are likely not to make any money either.

It is really unlikely that anyone is going to get paid for product that even does treat coronavirus, Skorney said. its not going to be something that companies are going to be able to generate a substantial profit, he said.

Read the original:
Biotech stocks get a boost from coronavirus fears -- but here's why investors should be wary - Yahoo Finance

Read More...

Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology – InvestorsObserver

February 8th, 2020 3:47 am

Halozyme Therapeutics, Inc. (HALO) is near the top in its industry group according to InvestorsObserver. HALO gets an overall rating of 54. That means it scores higher than 54 percent of stocks. Halozyme Therapeutics, Inc. gets a 60 rank in the Biotechnology industry. Biotechnology is number 51 out of 148 industries.

Click Here to get the full Stock Score Report on Halozyme Therapeutics, Inc. (HALO) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $20.83 as of 10:15 AM on Wednesday, Feb 5, a rise of $1.53, or 7.9% from the previous closing price of $19.30. The stock has traded between $20.06 and $21.28 so far today. Volume today is low. So far 663,847 shares have traded compared to average volume of 1,434,881 shares.

To see the top 5 stocks in Biotechnology click here.

Read the original post:
Is Halozyme Therapeutics, Inc. (HALO) Stock a Good Buy in Biotechnology - InvestorsObserver

Read More...

Where Is The Biotech Market Heading? – CIO Applications

February 8th, 2020 3:47 am

Innovation-driven biotechnology companies are all set to generate profit in the future years by executing value-based business and marketing strategies.

FREMONT, CA: Today, the availability of a broader range of high-tech applications has contributed to transforming the biotechnology industry. From physical examinations to smartly extracting information, emerging innovations help biotechnologists explore new methods to enable market expansion. Some of such trends revolutionizing the biotechnology sphere are listed below.

Digitally Driven Research

Adopting technology-based tools and applications help the modern-day professionals tackle market challenges by delivering the quality, safety, and efficacy of biotechnology products and services. The changing biotechnology demands can be achieved by upgraded tools and applications to perform researches in an advanced and instant manner. In recent years, biotechnology companies prefer digital research infrastructure, which enables them to collaborate with different experts from numerous locations and successfully examine bio components and properties.

Commercial Value-Based Pricing

It is high time for biotechnology products and service providers to set value-based pricing arrangements. The rising commercialization has increased the revenue streams; biotechnology providers can take advantage of data analytics to track customer demands and predict future market scenarios for strategically making decisions on different product pricing before the launch. Such a pricing arrangement can frame the real-time and measurable value of the biotechnology companies while attracting more stakeholders to invest in.

Automatic Conformance to Regulations

The rapidly advancing biotechnology companies need to follow different rules and regulations for testing and trading drugs. Tech-driven operational infrastructures offer smart features like automatically upgrading operational processes according to the upgraded rules and sending alerts regarding new regulations across the organization. Technology delivers the ability to access massive information from multiple resources for performing data-driven research processes.

With technology creating brilliant business opportunities, innovative solutions for biotechnology companies help the developments in genomics, proteomics, drug discovery, and more. The increasing pace of tech interventions in the industrial ecosystem has encouraged many investors to support biotechnology companies.

Originally posted here:
Where Is The Biotech Market Heading? - CIO Applications

Read More...

Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 – TheLoop21

February 8th, 2020 3:47 am

The Overview for Agricultural Biotechnology Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 20202029

We at MarketResearch.biz will help your business by providing the latest market reports containing all the data required to capture opportunities while increasing effectiveness. The report on Agricultural Biotechnology Market has been prepared with the help of modern analytical techniques such as SWOT Analysis and PESTLE Analysis which not only covers the technical areas but also the political and ecological factors that are affecting the market. Our report will help by providing a calculated forecast so as to make business aware of incoming possible opportunities and or problems.

Leading Market players like KWS SAAT SE & Co. KGaA, ChemChina, Limagrain, Nufarm, Marrone Bio Innovations, Performance Plants Inc., Corteva, ADAMA Ltd, MITSUI & CO., LTD, Evogene Ltd., Valent BioSciences LLC, Bayer AG. have been maintaining their position in the Global Agricultural Biotechnology market with the help of their up-to-date knowledge and readily available data to make an informed decision to effectively act on any opportunities that present itself.

***Access FREE PDF Sample Copy of the Report(Contains- Keyplayers, Growth Value, Segments, etc)! Click here***

Various classifications have been applied to the data to make it more readable to suit the eyes of a businessman. Following are some of the classifications provided in the report;

By Application:Vaccine DevelopmentTransgenic Crops and AnimalsAntibiotic DevelopmentNutritional SupplementsFlower CulturingBiofuels

By Organism Type:PlantsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesAnimalsConventional TechniquesEstablished Genetic ModificationNew Breeding TechniquesMicrobesConventional TechniquesEstablished Genetic ModificationNew Breeding Techniques

Regional Analysis:

1. North America (United States, Canada)

2. Europe (Germany, Spain, France, UK, Russia, and Italy)

3. Asia-Pacific (China, Japan, India, Australia, and South Korea)

4. Latin America (Brazil, Mexico, etc.)

5. The Middle East and Africa (GCC and South Africa)

Available Array of Customizations:

Country-level bifurcation of data in terms of Type and Application for any specific country/countries.

Expansion of scope and data forecasts until 2029

Company Market Share for specific country/countries and regions

Customized Report Framework for Go-To-Market Strategy

Customized Report Framework for Merger & Acquisitions and Partnerships/JVs Feasibility

Customized Report Framework for New Product/Service Launch and/or Expansion

Any other Miscellaneous requirements with feasibility analysis

*****Any query?Inquire/Share Your Questions HereOr Report Customization*****

Which prime data figures are included in the report?

-Market size (Last few years, current and expected)

-Market share analysis as per different companies

-Market forecast

-Demand

-Price Analysis

-Market Contributions (Size, Share as per regional boundaries)

Who all can be benefitted out of this report?

-Market Investigators

-Teams, departments, and companies

-Competitive organizations

-Individual professionals

-Vendors, Buyers, Suppliers

What are the crucial aspects incorporated in the report?

-Industry Value Chain

-Consumption Data

-Market Size Expansion

-Key Economic Indicators

In this study, the years considered to estimate the market size of the Agricultural Biotechnology are as follows:

Base Year:2019 | Estimated Year:2020 | Forecast Year: 2020 to 2029

Factors such as industry value chain, key consumption trends, recent patterns of customer behaviors, overall spending capacity analysis, market expansion rate, etc. The report also incorporates premium quality data figures associated with financial figures of the industry including market size (in USD), expected market size growth (in percentage), sales data, revenue figures and more. This might enable readers to reach quicker decisions with data and insights at hand.

The report caters to the subsequent questions pertaining To the Agricultural Biotechnology market:

Which Regional market is very likely to witness the maximum growth in terms of talk and value?

What Are the latest trends in the sector that is Agricultural Biotechnology?

What Is the forecasted value of this Agricultural Biotechnology economy in 2019?

Which End-use is likely to gain significant traction?

How Have advancements impacted the production procedures of this Agricultural Biotechnology in the last several years?

Purposes Behind Buying Agricultural Biotechnology Report:-

-> This report gives a stick direct examination toward changing focused elements.

-> It gives a forward-looking perspective on changed elements producing or restricting business sector improvement.

-> It gives a five-year evaluation surveyed based on how the market is anticipated to develop.

-> It helps in understanding the essential part sections and their prospect.

-> It gives stick point investigation of changing competition components and keeps you in front of contenders.

-> It helps in settling on educated business decisions by having complete bits of knowledge of the market and by making a top to bottom investigation of market fragments.

The Agricultural Biotechnology Market report concludes with sharing vital report findings with readers. Here on the basis of the study of historical data, the examination of the current scenarios overserved in various markets including regional and domestic and trends recorded, it delivers a forecast of the market. This includes segmental forecast, market size forecast, regional market forecast, consumption forecast.

Why Pick Marketresearch.biz?

Systematic Market research procedure

Data Gathered from credible and dependable secondary and primary resources

Team Of highly trained and skilled analysts with a profound comprehension of the most recent market research methods

Swift and efficient ordering process

Round the clock customer support catering to inquiries from global and domestic Customers

TO Download Detailed TOC ofAgricultural Biotechnology Market@https://marketresearch.biz/report/agricultural-biotechnology-market/#toc

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300, New York City, NY 10170, United States

Tel: +1 347 826 1876

Thanks a million for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest.

See the original post here:
Inclusive comprehension of Agricultural Biotechnology Market Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - TheLoop21

Read More...

Look Vir Biotechnology (VIR) Stock Where Its Heading? – News Welcome

February 8th, 2020 3:47 am

Vir Biotechnology (VIR) Stock Volatility Indicators To Watch:

Volatility of the Vir Biotechnology remained at 23.33% over last week and shows 11.80% volatility in last month. In addition to number of shares traded in last few trading sessions volatility also tells about the fluctuation level of the stock price, commonly a high volatility is the friend of day traders. Volatility is also measured by ATR an exponential moving average (14-days) of the True Ranges. Currently, the ATR value of companys stock is situated at 2.71.

Vir Biotechnology (VIR) has a market capitalization of $2.21B. Knowing about the market capitalization of a company helps investor to determine the company size, market value and the risk. The stock declined -14.36% to value at $22.81 on Monday trading session. VIR recorded volume of 1199133 shares in most recent trading session as compared to an average volume of 268.65K shares. It shows that the shares were traded in the recent trading session and traders shown interest in VIR stock. The stock EPS is $-1.26 against its recent stock value of $22.81 per share.

Looking into the Profitability indicators on Vir Biotechnology stock we analyze the stocks Profitability ratios.

Profitability Spotlight for Vir Biotechnology:

Return on Investment (ROI) of stock is 66.00%. ROI ratio tells about the efficiency of a number of investments in a company.

The price-to-earnings ratio or P/E is one of the most widely-used stock analysis tools to determine a stocks valuation

Analysts Estimation on Stock:

The current analyst consensus rating stood at 2.2 on shares (where according to data provided by FINVIZ, 1.0 Strong Buy, 2.0 Buy, 3.0 Hold, 4.0 Sell, 5.0 Strong Sell). Analysts opinion is also an important factor to conclude a stocks trend. Many individual analysts and firms give their ratings on a stock. While Looking ahead of 52-week period, the mean Target Price set by analysts is $26.

Now entering into the performance part of the article on Vir Biotechnology stock we should check the stocks actual performance in the past.

Performance of the VIR Stock:

Vir Biotechnology revealed performance of -7.95% during the period of last 5 trading days. The stock maintained for the month at 87.70%. The stock noted year to date 2019 performance at 81.35% and changed about 61.74% over the last three months. The stock is now standing at -21.36% from 52 week-high and is situated at 95.74% above from 52-week low price.

Technical Indicators of Vir Biotechnology Stock:

RSI momentum oscillator is the most common technical indicator of a stock to determine about the momentum of the shares price and whether the stock trading at normal range or its becoming oversold or overbought. It also helps to measure Speed and change of stock price movement. RSI reading varies between 0 and 100. Commonly when RSI goes below 30 then stock is oversold and stock is overbought when it goes above 70. So as currently the Relative Strength Index (RSI-14) reading of Vir Biotechnology stock is 63.39.

Although it is important to look for trades in a direction of bigger trends when stocks are indicating an opposite short-term movement. Like looking for overbought conditions when bigger trend remained down and oversold conditions when bigger trend is up. In order to check a bigger trend for VIR a 14-day RSI can fell short and considered as a short-term indicator. So in that situation a Simple moving average of a stock can also be an important element to look in addition to RSI.

The share price of VIR is currently up 34.32% from its 20 days moving average and trading 58.72% up the 50 days moving average. The stock price has been seen performing along above drift from its 200 days moving average with 59.36%. Moving averages are an important analytical tool used to identify current price trends and the potential for a change in an established trend. The simplest form of using a simple moving average in analysis is using it to quickly identify if a security is in an uptrend or downtrend.

Read the original here:
Look Vir Biotechnology (VIR) Stock Where Its Heading? - News Welcome

Read More...

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs – Benzinga

February 8th, 2020 3:47 am

The following is a roundup of top developments in the biotech space over the last 24 hours:

(Biotech stocks that hit 52-week highsFeb. 5.)

(Biotech stocks that hit 52-week lows Feb. 5.)

See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Sanofi SA (NASDAQ: SNY) said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, with the candidate significantly reducing disease activity associated with multiple sclerosis. The candidate was also found to be safe and well-tolerated.

Separately, the company released financial results thatshowed 6.8% net sales growth for the fourth quarter, driven by Dupixent and vaccines, and 253.5% net income growth. The company said it expects 2020 business EPS to grow 5% at constant currency.

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said it has decided to stop enrollment in the Phase 3 study dubbed RECOVERY that evaluated its Tonmya 5.6mg in treating post-traumatic stress disorder, following interim analysis of data by the Independent Data Monitoring Committee.

The IDMC sought stoppage of the trial for futility as it believed the experimental drug is unlikely to demonstrate a significant improvement in the primary endpoint of overall change from baseline in the severity of PTSD symptoms between the treatment and control arm.

The shares were plunging 59.91% to 68cents in premarket trading Thursday.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced positive interim results from ongoing Phase 1/2a studies of its two RNAi-based cardiometabolic candidates: ARO-APOC3, which is being evaluated for severe hypertriglyceridemia, and ARO-ANG3, whichbeing evaluated for dyslipidemias and metabolic diseases.

The company also released fourth-quarter results, showing a sales decline of 15% to $29.46 million and a loss of 3 cents. Analysts estimated a loss of 1 cent per share for the quarter.

The stock was trading 7.5% higher to $47 in Thursday's premarket session.

Misonix Inc (NASDAQ: MSON) reported 17.3% revenue growth on a pro forma basis for its fiscal year second quarter, and its net loss widened year-over-year. The company reiterated its fiscal year 2020 outlook for revenue growth in excess of 20% and gross margins of about 70%.

The stock rose 5.97% to $19 in after-hours trading.

Cardiovascular Systems Inc (NASDAQ: CSII) reported a wider-than-expected seond-quarter loss, while revenueclimbed 13.5%. The company raised the low end of its 2020 revenue guidance.

The stock shed 1.94% to $44 in after-hours trading.

Applied Genetic Technologies Corp (NASDAQ: AGTC) said it has commenced an underwritten public offering of 6 million shares of its common stock. All the shares are being offered by the company.

The stock slipped 9.70% to $6.33 in after-hours trading.

Jounce Therapeutics Inc (NASDAQ: JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors.

Beam Therapeutics said it has priced its upsized initial public offeringof 10.59 million shares at $17 per share, at the upper end of the estimated price range of $15-$17. The shares of the company, which is engaged in developing therapies based on single-base gene editing, will begin trading on the Nasdaq under the ticker symbol "BEAM."

Contract research organization PPD priced its 60-million share IPO at $27 compared to the initially estimated range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."

Related Link: Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

More here:
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs - Benzinga

Read More...

Germany Joins the Genomes Initiative – Lexology

February 8th, 2020 3:46 am

In January, Germany joined the EU's "1+ Million Genomes Initiative". While the German government had previously declined to actively participate in the project and Germany had merely assumed the role of an observer, it can now become involved in sharing genome data across Europe for research purposes. Genome analysis is not only instrumental to the future diagnosis, prevention and treatment of rare diseases, it is also an important economic factor in digital health.

1. GENOME SEQUENCING

Human genomes are made up of at least 20,000 genes containing all our genetic information. Genome sequencing allows us to decode almost all mutations in human genomes. This enables us to identify individual gene defects causing diseases and thus to better diagnose and treat rare diseases. Increasingly, whole genome sequencing is being used in the field of tumours to identify mutations and tailor medication to the genetic makeup of a specific tumour.

But although the development of new technologies such as high throughput DNA sequencing over recent years has made it much easier and faster to carry out human genome research, the mutations that cause disease have been determined only for around 4,000 of the 20,000 protein-coding human genes. Medical researchers will probably need decades to identify all genetic causes of disease.

2. THE EU'S GENOME INITIATIVE: 1 MILLION GENOMES BY 2022

In order to produce reliable scientific findings, researchers need broad access to genomic data from both healthy and sick patients. The aim of the EU's Genome Initiative is to collect at least one million sets of genomic data by 2022 and make these accessible beyond EU borders. The initiative is part of the EU's agenda for the digital transformation of health and care, which is aimed at harnessing the potential of new digital technologies to improve healthcare. In a declaration published in April 2018, EU, EEA and EFTA countries agreed to work together to build up and link genome databases to form a suitable technical infrastructure. So far, 21 EU member states and Norway have signed the declaration. Ten specialised working groups have been set up to look into ethical, legal and social issues, common data standards, best practices for sequencing, issues relating to health economics, research and public sector participation, as well as to analyse uses for rare diseases, cancer and common complex diseases.

3. CURRENT LEGAL SITUATION IN GERMANY

The current market leaders in genome analysis are the USA, China, the UK and some EU member states from Continental Europe. While other countries have already introduced whole genome sequencing as a standard procedure in genetic diagnostics and have produced millions of sets of data, Germany has only generated tens of thousands of data sets from whole genome sequencing. This cautious approach was put down to the particularly high level of interoperability required and restrictions due to data protection regulations.

There are certainly still some legal and also financial obstacles to be overcome in Germany. Although the German Genetic Diagnostics Act (Gendiagnostikgesetz, "GDA") provides a legal framework for genome sequencing for medical purposes and establishing parenthood, there is no specific legislation governing genome analysis for research purposes.

Genetic Diagnostics Act on genome analysis for medical purposes and establishing parenthood

Genome analysis for medical purposes entails diagnostic and predicative genetic testing. Like genome analysis to establish parenthood, it is governed by the GDA. It stipulates that doctors have to provide genetic advice, restricts genome testing and analysis to doctors with appropriate training and provides for a patient's right "not to know" the results. Moreover, according to the GDA, patients must be given comprehensive information on the procedure beforehand and they must grant their consent.

Genome sequencing has already become part of standard care in Germany and since mid-2016 has been included in the German physicians' fee schedule. However, unlike in England, the German system does not cover sequencing of whole genomes but only of a very small gene panel of up to 25 kilobases, which corresponds to an average of four genes. For some diseases, up to 1,000 genes need to be analysed. Doctors wishing to perform larger sequencing projects have to apply for extra-budgetary services. Since such applications have often been rejected in the past due to the strict requirements, there is currently no incentive for physicians to perform medical genome analysis.

Pursuant to the GDA, genetic testing to establish parenthood requires the consent of the individuals providing the samples and can also be performed by specialists not qualified as doctors, for instance molecular biologists. Unlike in the USA, for example, analyses performed privately are not permissible.

No specific legislation on genome analysis for research purposes

The German legislator deliberately decided not to extend the scope of the GDA to cover genome analysis for research purposes, including general research on the factors affecting human characteristics. By contrast to predictive genetic testing, such research is not aimed at developing specific treatment for specific individuals. This means there are no specific regulations in this field of research, so the general statutory provisions apply.

Therefore, for related clinical studies, the general German laws on medicinal products and medical devices apply. They require that participants be provided with full information on any testing and must grant their prior consent. Since genome analysis involves collecting personal data, the General Data Protection Regulation (GDPR) and national data protection regulations also apply. Article 9 of the GDPR classifies genetic data as sensitive data that may only be processed if the data subject has given their explicit consent or with special legal permission. However, the German legislator took advantage of the exemption clauses in Article 89 (2) GDPR. Article 89 states that genetic data may be processed for scientific research purposes even without consent if it would otherwise be impossible to fulfil such purposes and the interests of the party responsible for processing the data significantly outweigh the interests of the data subject in not having data processed. Given the significance of genome sequencing for research, the consent requirement could therefore be dispensed under data protection regulations.

However, this would breach the strict laws on medicinal products and medical devices which require consent to the use of data in clinical studies. Data protection law also entitles data subjects to request information on their data or have their data deleted. This may be difficult to put into practice if large amounts of data have been collected. Another point to be clarified is whether individuals have a right to know or not to know about random genetic findings.

Ultimately, in the absence of specific legislation on genome analysis for research purposes, many legal questions have yet to be answered. It remains to be seen whether the legislator will set out more precise regulations in future.

4. WHERE DO WE GO FROM HERE?

The Federal Ministry of Research (Bundesforschungsministerium) has announced that the next step will be to set up national working groups. A detailed schedule and set of requirements are to be drawn up by mid-2021. Only then will it be possible to develop strategies for the cross-border use of genomic and phenotypic data. According to the Ministry, the first locations for testing the secure sharing of genomic data are to be selected by the end of 2020. On that basis, it will be possible to donate genomes during clinical treatment.

By joining the Genome Initiative, Germany has taken an important step in terms of digital health. Now the task is to adjust the existing legal framework to cover whole genome sequencing and to clarify the remaining legal issues. In future, genome analysis will play a key role not only for major pharmaceutical companies, manufacturers of medical devices, hospitals and research institutes, which are directly or indirectly involved in researching rare diseases, but also for investors. To meet today's legal and regulatory challenges and any further challenges the future may bring, all players will have to keep a close eye on developments in this field.

Follow this link:
Germany Joins the Genomes Initiative - Lexology

Read More...

This Founder Couldn’t Find an Affordable Way to Test Drinking Water After the Flint Crisis, so She Created One – Inc.

February 8th, 2020 3:46 am

Editor's note:This article is part of Inc.'s 2020 Best Industries report.

"I love my family, but that's ridiculous," Glover says.

That same year, Glover co-founded120 Water Audit to develop more affordable consumer water testing kits. Now the company also tests and manages drinking water programsfor government agencies, public water systems, schools, and other facilities.120 Water Audit is a leader among a growing group of startups serving utility companies and government agencies that have been forced to update systems and respond togrowing consumer concerns in the wake of crises like Flint.

Turning on the tap

Glover, a former marketing and business development executive, launched 120 Water Audit with co-foundersChris Baggott and Dave Kohl.(Baggott and Kohl were never operational with the company, but Baggott is on the board of directors.) They initially bootstrapped the business and worked out of Glover's parents' garageuntil the company won its first contracts with the city ofPittsburgh, the state of Indiana, andutilities in Loveland, Colorado, and Lewisville, Texas.

To collect samples, the startup sends water bottles that customers fill from the source they wish to test.Each bottle comes with a prepaid return envelope that goes to an EPA-certified lab for testing. Individual water tests rangefrom $54 to $84, depending on the type of analysis. Meanwhile, the company's software helpsclientsaggregate data and automate tasks like sending recurring reports.

120 Water Audit's tests detecttoxins like lead, copper, and arsenic, whichat certain levels have been linked to learning problemsamong children, reproductive issues, and, in rare cases, death, according to the Environmental Protection Agency. Some of these contaminants occur naturally, while othersmake their way into water supplies from manufacturing facilities orinfrastructure failuressuch asold pipes. The Flint water crisis is one of the most recent instances of the latter: The city switched its water source in 2014;officials failed to treat the water and lead from older pipes seeped in.Some residents experienced lead poisoning, while low chlorine levels led to a deadly outbreak of Legionnaire's disease.

The Flint crisis raised consumer awareness of drinking water safety, and as a result,120 Water Audit has seen a steady risein sales since its launch. The company--named for the frequency it believes consumers should test their water, which is every 120 days--booked $3.3 million in revenue last year, up from about $2 million in 2018. Glover declined to share whether the company was profitable.

A flood of activity

Glover's startup isn't the only one to see an increase in activity: Last year, businesses working on clean water initiatives--which tackle a broad array of services, including producing drinkable water from new sources and real-time water monitoring--raised $50.7 million in venture capital funding, according to the data and research company PitchBook. That's a $10.9 million increase from 2014, but it's stilla relatively low amount of VC funding for an entire industry.

120 Water Audit wasone of the best-funded startups in the industry last year: It raised $7 million in venture capital, which makes up 13.8 percent of theindustry's totalventure capital dollars from last year, according to Pitchbook. In total, the company has raised $9.4 million, including a$100,000 first prize from former America Online CEO Steve Case's Rise of the Rest pitch competition. Glovercredits a majority of 120 Water Audit's growth to newly implemented drinking water regulations and stricter water quality specifications in the wake of Flint.

"Consumers are getting a lot more vocal about the quality of their water," she says. "That's forcing [traditional water utility companies] to think differently about the programs they run and how they communicate with consumers."

Crises like Flintare leading consumers to take action by using theseservices or pushing government agencies for more testing,says Reese Tisdale, the president and CEO of Bluefield Research, an independent advisory firm that aims to help companies and organizations address regulatory and business trends in the water sector. "We expect to know what we're ingesting and understand what the impacts are on ourselves and the environment."

Today, 120 Water Audit works with clients in 14 states, including four statewide contracts, and its software has been implemented on more than 175,000 taps, Glover says. The majority of the business is built on partnerships with water systems, while about a fourthgoes to state contracts, says Glover. However, she still receives a steady trickle of individual consumers seeking her water testing kits, but that makes up less than 1 percent of the company's revenue, Glover added.Prices vary depending on the customer's location and size of its water program, but the company's average contract value is just under $270,000 per year.Currently, Glover employs a team of 36 workers.

However, the startup still faces industry-specific challenges, like heavy regulation and a lack of funding from investors."It's not a technology problem, it's that there aren't enough dollars to go around," Tisdale says. "There is no white knight out there with bags of money to save your municipal water supply."

What's more, startups in the clean water space will face stiff competition from larger companies that offer diversified services and have the financials to withstand market changes or slow adoption rates, Tisdale says. Prominent U.S.-based heavyweightsinclude Xylem and Danaher, both of which are public companies that own multiple brands in the clean water space, he adds.

Glover is lookingto expand 120 Water Audit's reach by launching a commercial application later this year. The program would give safe drinking water certifications to establishments like hotels and restaurants.

As for the results of the water analysis in her own home, Glover was relieved to learn her tap water was safe. She says she wants to give many more people the same peace of mind. "Once you know a lot of this stuff, you can't unknow it."

Published on: Feb 4, 2020

Read more here:
This Founder Couldn't Find an Affordable Way to Test Drinking Water After the Flint Crisis, so She Created One - Inc.

Read More...

An Ex-NASA Employee Is Launching Satellites Into Space to Predict the Future and Help Save Lives – Inc.

February 8th, 2020 3:46 am

When Malaysia Airlines Flight 370 disappeared on its way from Kuala Lumpurto Beijingin 2014, aerospace engineer Payam Banazadeh, then 23, fixated on one question: Why couldn't satellites scan the area where the plane disappeared in real-time?

"As I pulled the thread, what was very clear was that there was a huge gap in monitoring our planet from space," Banazadehsays.

Of thehundreds of schoolbus-size Earth-observation satellites currently in orbit, the majority use optical imaging, which typically can't see 75 percent of the Earth's surface because of weather issues and darkness, according to Banazadeh. At the same time, the cost of sending satellites into orbit is falling dramatically as governments and private companies launch a growing number of rockets into space, creating new opportunities for entrepreneurs to puteyes in the sky.

Banazadeh, a former project manager at NASA, saw a problem he could solve and the perfect moment to do it, so he founded Capella Space in 2016 with the goal of developing a smaller, more powerful satellite. In 2019, the company launched its first prototype satellite Denali, a backpack-size device that uses a technology called Synthetic Aperture Radar (SAR), which can see through clouds and at night.

In 2020, Capella will launch sevensatellites that togetherwill be able to monitor the entire surfaceofthe planeteverysix hours, on average, according to Banazadeh. The company will launch an additional sixto 12 satellites per year until it has 36 in orbit, at which point he says the time between updates will drop from up six hours to up to one hour. Capella will allow customers to submit requests for data and imagery through an automated system in a matter of minutes,16 times faster than rivalcompanies can, according to Banazadeh.

A wide range of applications

Unlike optical imaging satellites, which relyon incominglight to produce an image, Capella's satellites send a radar signalthat hits the Earth's surface and is reflected back to the satellite.The resulting data is used to produce an image that can detect changes tothe Earth's surfaceless than a meter in size. The structural integrity of a bridge, for example, can be monitored over time to determine whether maintenance workneeds to be done.

Although Capella's fleet of satellites isn't commercially operational yet,the companyhas already signed multimillion-dollar contracts with U.S. government agencies, including the U.S. Air Force and the Department of Defense's National Reconnaissance Office. "We will be monitoring certain spots for them and alerting them of any change," Banazadeh says.

The applications for Capella's servicesextendfar beyond providing information for governmentagencies.Banazadehsaysthe companyhas deals in place with private sector customers, thoughhe can't disclose their names.Being able to trackthe supply chain ofmajorcommodities like oil is onecapability hesays will create significant value.And because Capella's radar can also measurethe moisture levels of soil, monitoringthe health of crops for the agricultural industry represents another opportunity. Perhaps the most valuable service will beprovidinginformation tofirst responders during emergencies like storms, fires, andother natural disasters.

"The ability for us to immediately look through the clouds while the storm or disaster is happening, do damage assessment, and provide thatto the first responders to tell them what the best route is--those are the types of interactions we can start having," Banazadeh says.

Lower costs mean greater opportunity

With around 100 rocket launches taking place every year,the cost of sending satellitesinto space has fallen to between $20,000 and $40,000per kilogram. "It used to be that governments would launch these gigantic, billion-dollar satellites into space once every couple years," says Todd Dagres, a co-founder at Spark Capital, one of Capella's investors. "What's happened is, the bar has dropped so precipitously that countries that before could hardly get a train to run on time are pumping iron to the sky."

Elon Musk's SpaceXrecently began offering monthly missions to small satellite operators starting at $1 million, or$5,000 per kilogramfor up to 200 kilograms of payload mass.(In March, Capella's first operational satellite, called Sequoia, is scheduled tolaunch on a SpaceX Falcon 9 rocket from Cape Canaveral, Florida.) Theindustry also has benefited from lower costs for the components required to build small satellites. "A lot of that is driven by the commercial electronics industry--the stuff that is feeding the newest features on our iPhones and laptops,"says Mike Safyan, vice president of launch at Planet, an Earth-observation company that provides satellite imagery data. "That's being folded into the space industry in a way that hasn't really been done before."Capella declined to disclose how much it costs to buildits satellites.

Venture capital investment into space technology companies hasgrown to $2.27 billion in 2019 from $2.6 million in 2011, according to market data provider PitchBook.Capella has raised more than $80 million in funding, primarily from venture capital firms Data Collective andSpark Capital. The global nanosatellite and microsatellite marketis expected to grow to $3.6 billion by 2024 from $1.5 billion in 2019, according to research firm MarketsandMarkets.

Companies that provide satellite observation services similar to Capella's, albeit using much larger satellites, include multinational aerospace corporation Airbus and Italian company e-GEOS.Banazadeh says the value Capella brings is significantlydifferent from what these companies can offer thanks to its constellation that can repeatedly observe specific areas of the planet.

"They have these giant satellites that can do more things thanour satellites can do, but they can't really have the cadence at the cost that we can provide," he says. "I think we're very much complementary with those guys."One startup competitor isJapaneseSAR company Synspective, which raised $100 million in funding last July. Twoof the biggest challenges facing all satellite companies, according to Banazadeh,aresecuring reliable launch vehicles andputting satellites into orbit on time, asrockets are in high demand and launch delays are the norm rather than the exception.

In as soon as the next five years, Banazadehsays Capella's data could be useful for predicting future events, like where illegal fishingis likely to take place.

"If I were looking at that area from space using my satellite and combining it with other satellites and other data--this is the route they take and this is what the boat looks like--the next time I can start predicting who is doing what," he says. "As we start building this really dense data set of high quality and high cadence, that's going to be really interesting."

Published on: Feb 4, 2020

See the original post here:
An Ex-NASA Employee Is Launching Satellites Into Space to Predict the Future and Help Save Lives - Inc.

Read More...

Page 693«..1020..692693694695..700710..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick